PROFESSIONAL

ACTOnco^® +

Comprehensive Cancer Genomic Profiling Service

Find the Right Treatment For Your Cancer Patient

ACTOnco^® +is developed with the aim of supporting and answering the clinical challenges faced during the management of major solid tumors, including carcinomas, sarcomas, and lymphomas. The ACTOnco<sup>®</sup>+ panel comprises 440 specially-curated genes, 13 fusion genes & more than 350 fusion transcripts and references the Hallmarks of Cancer to facilitate treatment strategies, including:Chemotherapy,Targeted therapy,Immunotherapy and Pharmacogenomics.

Cancer Signaling Pathway Analysis-Identify more treatment options with pathway integration

ACTOnco^® + comprehensively identifies genetic alterations of each signaling pathway to evaluate drug options based on upstream and downstream interactions. By incorporating comprehensive genomics profiling and integrating signaling pathway analysis, ACTOnco^® + provides clinicians with a more holistic understanding of the major cancer-driven events during tumorigenesis and provides more targeted therapeutic strategies.

ACTOnco^® +

Hallmark of ACTOnco^® +

Comprehensive Cancer Types
All Solid Tumors
Suitable for Most Patients
- Newly diagnosed with complex cancer type
- Recurrent and metastastic cases
- Patient searching for treatment (and trials) options
- Diagnosed with advanced cancer or late-stage cancer
Comprehensive Report Content
- Genetic alterations, including BRCA1/2
- Therapeutic implications for FDA approved chemotherapy, hormonal therapy, targeted therapy, PARP1 inhibitors and immunotherapy drugs and other drugs used in clinical trials
- Prediction of immunotherapy response, including TMB and MSI status
- Pharmacogenomics information

WhyACTOnco^® +

Can Provide Comprehensive Solutions

Comprehensive Pathway-Based Panel
Sequencing of 440 cancer-related genes and 13 fusion genes & more than 350 fusion transcripts covering most key cancer signaling pathways for targeted therapy
Predicting immunotherapy response
Incorporating mutation burden, immune-related gene information and MSI status for a more accurate immunotherapy recommendation
Providing Pharmacogenetics information
Responses to treatment may be affected by inherited genetic variations (polymorphisms). Pharmacogenetics information can be used to match patients with the treatment that is most effective, while causing less side-effects.
Pioneering Bioinformatics
Integrating cancer biology, medical biology, molecular biology, cell biology, immunology, bioinformatics, data science, and pharmaceutical biology to provide insightful interpretation
Providing Report Consultation
Every report is complemented with a face-to-face consultation with our medical team.
Short Turnaround Time
Providing professional solutions within 10 working days. (starting from the day qualified specimen is received at lab)
High Sensitivity
Next Generation Sequencing (NGS) is used for microscale specimens.